“Transforming India’s Fight Against Breast Cancer: The Promise and Challenges of Germline Genetic Testing”

Germline genetic testing is transforming India’s approach to breast cancer prevention, offering new hope for earlier detection and personalized care. Recent studies show that these tests uncover significant hereditary risks, yet access and adoption remain limited, highlighting an urgent need for expanded guidelines and awareness across the country.

Germline Testing: The Essentials

Germline genetic testing analyzes inherited changes in DNA (mutations) that elevate the risk of diseases like breast cancer. In India, pathogenic mutations—most famously in the BRCA1 and BRCA2 genes—account for a notable proportion of hereditary breast cancers. However, recent research has identified other relevant genes (e.g., PALB2, TP53, ATM), broadening the scope of genetic risk factors for patients.

Key Findings from Indian Research

Emerging evidence paints a nuanced picture of genetic risk among Indian breast cancer patients:

• Studies among varied cohorts reveal pathogenic or likely pathogenic (P/LP) mutations present in approximately 18-44% of breast cancer cases, depending on the gene panel used.

• BRCA genes account for the majority of pathogenic variants—up to 88%—while about 12-34% are found in non-BRCA genes, reflecting unique population profiles.

• Mutations are more common in younger patients, those with triple-negative breast cancer, and individuals with a family history of breast or ovarian cancer.

Statistically, about 18–44 out of 100 Indian breast cancer patients could carry a hereditary mutation, compared with 2–10% in the general population globally.

Expert Perspectives

Dr. Sunita Saxena, National Institute of Pathology, ICMR, notes: “India’s unique genetic landscape necessitates more inclusive and population-specific guidelines for genetic testing—especially as high-risk alleles such as CYP17 and VDR continue to emerge as important factors”.

Prof. Clare Turnbull, The Institute of Cancer Research, London, comments: “Expanded gene panel testing can pick up otherwise overlooked risks but must be balanced with the reality that not all detected mutations translate to actionable clinical changes”.

Dr. Abhenil Mittal (Princess Margaret Cancer Center) underscores the need to tailor global testing criteria for local populations: “The sensitivity of international criteria remains inadequate for India, reiterating the need for expansion”.

Context: Why India Needs Better Germline Testing

Breast cancer is the most common cancer in Indian women, with incidence rising sharply among those younger than 40. Genetic factors play a larger role in younger patients’ risk profiles. However, current testing guidelines based on Western research may miss high-risk individuals due to genetic diversity and distinct environmental exposures (e.g., betel quid chewing).

Despite technological advances, uptake of cascade (family) testing is low, with only about 10% of eligible relatives receiving screening—leaving many unaware of their possible risk.

Implications for Public Health

• Personalized Prevention: Genetic testing enables targeted surveillance, early intervention, and preventive strategies (e.g., enhanced screening, risk-reducing surgeries) for carriers.

• Treatment Optimization: Mutation status informs therapy choices—BRCA positivity predicts sensitivity to platinum-based chemotherapy and PARP inhibitors.

• Family Impact: Cascade testing can help identify at-risk relatives, allowing for proactive health management.

Barriers and Limitations

Exclusive reliance on gene panels focused only on BRCA1/2 risks missing sizable fractions of hereditary cancers, especially in diverse populations like India. Additional challenges:

• Limited awareness and access

• Psychological impact and genetic counseling gaps

• Variability in guidelines across institutions

• Potential for variants of uncertain significance (VUS), leading to anxiety or confusion

Some experts caution about overscreening with large “pan-cancer” panels, which may detect mutations with unclear clinical relevance, possibly increasing emotional burden and healthcare costs.

Practical Takeaways

For health-conscious individuals:

• Consider discussing family history and personal risk with healthcare providers.

• Recognize that not all positive genetic findings indicate high cancer risk.

• Early testing offers options for enhanced screening or preventive measures.

For clinicians:

• Stay updated with evolving, locally validated criteria for genetic testing.

• Integrate counseling to address emotional and informational needs.

For policymakers:

• Strengthen population-specific guidelines for genetic testing access within India’s national health programs.

• Increase awareness and reduce barriers to cascade testing.

Balanced Perspectives

While genetic testing can revolutionize breast cancer care, its true impact depends on equity of access, rigorous counseling, and robust, locally-tailored guidelines. New evidence must be integrated responsibly, with care to avoid blanket screening where the benefit is unproven.

Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References